Sanofi (NASDAQ:SNY) Stock Rating Lowered by StockNews.com

StockNews.com cut shares of Sanofi (NASDAQ:SNY) from a buy rating to a hold rating in a report released on Thursday.

Separately, Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

Shares of Sanofi stock opened at $46.99 on Thursday. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. The firm has a market cap of $119.25 billion, a price-to-earnings ratio of 23.97, a price-to-earnings-growth ratio of 1.24 and a beta of 0.58. Sanofi has a one year low of $45.22 and a one year high of $58.97. The stock’s 50-day moving average is $51.19 and its 200-day moving average is $52.05.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. The company had revenue of $13.44 billion for the quarter, compared to the consensus estimate of $16.59 billion. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm’s revenue was up 12.3% compared to the same quarter last year. During the same period last year, the company earned $2.55 earnings per share. Equities analysts predict that Sanofi will post 4.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its stake in Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after acquiring an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC grew its holdings in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares during the last quarter. Franklin Resources Inc. lifted its stake in Sanofi by 13.1% in the 3rd quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock valued at $208,106,000 after purchasing an additional 395,744 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after buying an additional 246,224 shares in the last quarter. Finally, Federated Hermes Inc. grew its stake in shares of Sanofi by 26.5% during the second quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock worth $155,950,000 after buying an additional 673,172 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.